Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)
Today, Credit Suisse Group raised its price target on Alexion Pharmaceuticals (NASDAQ:ALXN) to $149.00 per share.
Some recent analyst ratings include
- 3/9/2018-Cowen Reiterated Rating of Buy.
Recent Insider Trading Activity For Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) has insider ownership of 4.35% and institutional ownership of 95.38%.
- On 2/28/2018 Heidi L Wagner, SVP, sold 698 with an average share price of $119.35 per share and the total transaction amounting to $83,306.30.
- On 2/28/2018 Julie O’neill, EVP, sold 1,625 with an average share price of $119.83 per share and the total transaction amounting to $194,723.75.
- On 2/8/2018 Heidi L Wagner, SVP, sold 1,774 with an average share price of $116.31 per share and the total transaction amounting to $206,333.94.
- On 2/8/2018 John B Moriarty, EVP, sold 3,363 with an average share price of $115.70 per share and the total transaction amounting to $389,099.10.
- On 2/8/2018 Ludwig Hantson, CEO, sold 13,245 with an average share price of $116.31 per share and the total transaction amounting to $1,540,525.95.
- On 2/8/2018 Paul J Clancy, CFO, sold 6,079 with an average share price of $116.31 per share and the total transaction amounting to $707,048.49.
- On 2/5/2018 Heidi L Wagner, SVP, sold 655 with an average share price of $117.26 per share and the total transaction amounting to $76,805.30.
Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at 129.51 up +2.68 2.11% with 126.2300033569336 shares trading hands.